The convergence of precision genetic science and expanding clinical applications is fueling one of biotechnology’s fastest-growing sectors. A recent industry review of the genome editing market found that the global industry, valued at USD 5.67 billion in 2023, is expected to grow from USD 6.39 billion in 2024 to USD 16.63 billion by 2031, reflecting a compound annual growth rate (CAGR) of 14.64% during the forecast period. The surge is being driven by breakthroughs in CRISPR-based technologies, rising investment in genetic disorder research, and the accelerating commercialization of gene-editing therapies.
What Is Driving the Genome Editing Boom?
Genome editing refers to the precise modification of an organism’s DNA, allowing scientists to add, remove, or alter genetic material at specific locations within the genome. Technologies such as CRISPR-Cas9, TALENs, and zinc finger nucleases have transformed this once-niche scientific discipline into a mainstream driver of innovation across medicine, agriculture, and biotechnology. By enabling researchers to correct genetic disorders, engineer novel therapies, and enhance crop resilience, genome editing has become foundational to the future of personalized medicine and agricultural biotechnology alike.
Enhanced regulatory frameworks are also playing a critical enabling role, facilitating faster progression of clinical trials and smoother pathways to commercialization for gene-editing therapies. This regulatory maturation, paired with continued technological refinement, is expanding the addressable applications for genome editing well beyond its original research-lab origins.
CRISPR: The Engine of Market Growth
Among the various editing technologies tracked in the market, CRISPR stands out as the dominant force, having generated USD 3.53 billion in revenue in 2023 alone. The technology’s expanding footprint across medical research, drug development, and agricultural science continues to reinforce its market leadership. Continuous refinements to CRISPR techniques are improving both the precision and efficiency of genetic modifications, while rising investment in CRISPR-based therapeutic partnerships is accelerating the pace of innovation.
A landmark moment for the technology arrived in November 2023, when the UK’s Medicines and Healthcare products Regulatory Agency approved CASGEVY (exagamglogene autotemcel), developed by Vertex and CRISPR Therapeutics, marking the first-ever approval of a CRISPR/Cas9 gene-editing therapy for sickle cell disease and beta-thalassemia—conditions that have traditionally required lifelong blood transfusions. This approval has served as a proof point for the broader industry, demonstrating the real-world clinical and commercial viability of CRISPR-based treatments.
Funding Momentum Fuels Innovation
Robust funding from both public and private sources continues to underpin the sector’s rapid expansion. The National Institutes of Health’s Somatic Cell Genome Editing Program, for example, awarded 24 additional grants to U.S. and Canadian researchers as of June 2022, contributing USD 89 million in new funding over four years and bringing total program support to approximately USD 190 million across 45 projects over six years. Such large-scale institutional funding is enabling companies to pursue cutting-edge research, forge strategic partnerships, and expand their therapeutic pipelines.
Corporate collaboration activity has also intensified. In February 2024, Precision BioSciences granted Caribou Biosciences a non-exclusive global license, with sublicense rights, to one of its key cell therapy patent families—permitting the combined use of Precision’s ARCUS gene-editing platform alongside CRISPR technology for human therapeutic applications. Similarly, Sangamo Therapeutics and Chroma Medicine entered into a research evaluation, option, and license agreement in July 2023 to jointly develop epigenetic medicines utilizing zinc finger proteins for precise DNA targeting.
Market Segmentation
By application, cell line engineering represented the largest segment in 2023, capturing 45.78% of total market share. This dominance stems from surging demand for customized cell lines used in producing targeted proteins and biopharmaceuticals, along with continuous advancements in cell culture and genetic modification techniques that improve the efficiency and scalability of cell line development.
From an end-user perspective, pharmaceutical and biotechnology companies are expected to generate the highest revenue—an estimated USD 10.34 billion by 2031—as these organizations continue to funnel substantial R&D investment into genome-editing-based treatments for cancer, genetic disorders, and other complex diseases. Strategic collaborations between pharmaceutical firms and biotechnology innovators are further accelerating the pace of development and commercialization within this segment.
Regional Analysis
North America led the global genome editing market in 2023, commanding a 37.89% share worth approximately USD 2.15 billion. The region’s dominance is attributable to its robust research infrastructure, growing adoption of genetically modified crops, and rising prevalence of genetic diseases such as cystic fibrosis, all of which continue to fuel demand for advanced editing tools. A steady increase in patent approvals for U.S.-based innovators, coupled with substantial government funding for scientific research, has reinforced the country’s leadership position within the region.
Asia-Pacific, meanwhile, is projected to be the fastest-growing region, expanding at a striking CAGR of 17.62% through 2031, with market value expected to reach USD 4.22 billion. Countries including China, India, and Japan are leveraging genome editing advancements to strengthen agricultural output and advance medical research, supported by favorable government policy and expanding collaboration between academic institutions and biotechnology firms. The region’s growing healthcare infrastructure and rising burden of chronic disease are further amplifying demand for genome-editing solutions.
Educational and Institutional Momentum
Beyond therapeutic and agricultural applications, genome editing is also making inroads into science education. In March 2024, Carolina Biological Supply Company partnered with the ChristianaCare Gene Editing Institute to launch a specialized “CRISPR in a Box” educational kit, designed to introduce high school and college students to practical gene-editing techniques—an initiative that reflects the technology’s growing cultural and scientific footprint.
Competitive Landscape
The genome editing market remains fragmented, with participants pursuing partnerships, mergers, acquisitions, and product innovation to secure competitive advantage. Leading companies include Merck KGaA, Cibus Inc., Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and Cellectis. In January 2024, Danaher Corporation and the Innovative Genomics Institute launched the Danaher-IGI Beacon for CRISPR Cures, a collaborative center dedicated to advancing gene-editing therapies for rare and complex diseases through a unified strategy spanning research, development, and regulatory processes.
Outlook
With CRISPR-based therapies moving from experimental promise to regulatory approval and commercial reality, and with sustained funding continuing to flow into genetic disorder research, the genome editing market is poised for continued double-digit growth through the end of the decade. Stakeholders that can successfully navigate the intersecting demands of scientific innovation, regulatory compliance, and ethical oversight stand to capture significant value in this rapidly evolving space.
